A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1117-1123

  Kelly, Karen ^a   Pan, Zhaoxing ^a   Murphy, James ^a   Huffman, David H ^b   Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Pike's Peak Veterinary Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 0030873026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Souquet, P. J., Chauvin, F., Boissel, J. P., Cellerino, R., Cormier, Y., Ganz, P., Kaasa, S., Pater, J., Quoix, E., Rapp, E., Tumarello, D., Williams, J., Woods. B. L., and Bernard, J. P. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet, 342: 19-21, 1993.
2. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., and Invernizzi, F. Chemotherapy versus supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest, 106: 861-865, 1994.
3. Pignon, J. P., Stewart, L. A., Souhami, R. L., and Arriagada, R. A meta-analysis using individual patient data from randomized clinical trials of chemotherapy in non-small cell lung cancer: survival in the locally advanced setting. Proc. Am. Soc. Clin. Oncol., 13: 334, 1994.
4. Rowinsky, E., Onetto, N., Canetta, R., and Arbuck, S. Taxol: the first of the taxanes, an important new class of untitumor agents. Semin. Oncol., 19: 646-662, 1992.
5. Schiff, P., Fant, J., and Horwitz, S. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
6. Schiff, P., and Horwitz, S. Taxol stabiles microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
7. Murphy, W. K., Winn, R. J., Fossella, F. V., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, I., Dhingra, H., and Raber, N. M. A Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.
8. Chang, A., Kim, K., Click, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst., 35: 388-394, 1993.
9. Tan, V., Herrera, C., Einzig, A., and Wiernik, P. Taxol is active as a 3-hour or 24-hour infusion in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 14: 366, 1995.
10. Gatzemeier, U., Heckmayr, M., Neuhauss, R., Schluter, I., Pawel, J., Wagner, H., and Dreps, A. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer, 12: S101-S106, 1995.
11. Tester, W., Cohn, J., Desai, D., Reardon, D., and Cohen, M. Phase II study of continuous oral ifosfamide (IFOS) in advanced non-small cell (NSCLC) lung cancer. Proc. Am. Soc. Clin. Oncol., 14: 382, 1995.
12. Hainsworth, J., and Greco, F. Paclitaxel administered by 1-hour infusion: preliminary results of a Phase I/II trial eomparing two schedules. Cancer (Phila.), 74: 1377-1382, 1994.
13. Millward, M., Bishop, J., Friedlander, M., Levi, J., Goldstein, D., Olver, I., Smith, J., Toner, G., Rischin, D., and Bell, D. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 14: 142-148, 1996.
14. Klastersky, J., Sculier, J. P., Lacroix, H., Dabouis, G., Bureau, G., Libert, P., Richez, M., Ravez, P., Vandermoten, G., Thiriaux, J., Cordier, R., Finet, C., Berchier, M. C., Sergysels, F., Mommen, P., and Paesmans, M. A randomized study comparing cisplutin or carboplatin with etoposide in patients with advanced non-small cell lung cancer. J. Clin. Oncol., 8: 1556-1562, 1990.
15. Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Hams, J., and Comis, R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 7: 1602-1613, 1989.
16. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest. New Drugs, 10: 239-253, 1992.
17. Muggia, F., Vafai, D., Natale, R., Israel, V., Zaretsky, S., McRae, A., Rogers, M., and Jeffers, S. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin. Oncol., 22 (Suppl. 4): 63-66, 1995.
18. Rowinsky, E. K., Flood, W., Sartorius, S., Bowling, K., Wagner, J., and Ettinger, D. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin. Oncol., 22 (Suppl. 4): 48-54, 1995.
19. Giaccone, G., Huizing, M., Postmus, P., Huinink, W., Koolen, M., Zandwijk, N., Vermorken, J., Beijnen, J., Dalesio, O., Pinedo, H., and Veenhof, C. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol., 22 (Suppl. 4): 78-82, 1995.
20. Bunn, P., Jr. Clinical experiences with carboplatin (paraplatin) in lung cancer. Sernin. Oncol., 19 (Suppl. 2): 1-11, 1992.
21. Calvert, A. H., Newell, D. R., Grumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
22. Rowinsky, E., Gilbert, M., McGuire, W., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
23. Carboni, J., Singh, C., and Tepper, M. Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins. Natl. Cancer Inst. Monogr., 15: 95-101, 1993.
24. Langer, C., Leighton, J., Comis, R., O'Dwyer, P., McAleer, C., Bonjo, C., Engstrom, P., Litwin, S., and Ozols, R. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a Phase II toxicity, response, and survival analysis. J. Clin. Oncol., 13: 1860-1870, 1995.
25. Belani, C., Aisner, J., Hiponia, D., and Engstrom, C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol., 22: 63-66, 1995.
26. Rowinsky, E., McGuire, W., Guarnieri, T., Fisherman, J. S., Christian, M. C., and Donehower, R. C. Cardiac disturbances during the administration of Taxol. J. Clin. Oncol., 9: 1704-1712, 1991.
27. Johnson, D., Paul, D., Hande, K., and DeVore, R. F. Paclitaxel (Taxol) plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University Phase II trial LUN-46. Semin. Oncol., 22: 30-33, 1995.